With 0.62 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.14 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.635 whereas the lowest price it dropped to was $1.58. The 52-week range on PLX shows that it touched its highest point at $3.10 and its lowest point at $0.82 during that stretch. It currently has a 1-year price target of $15.00. Beta for the stock currently stands at -0.21.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PLX was up-trending over the past week, with a rise of 11.89%, but this was up by 18.52% over a month. Three-month performance dropped to -39.16% while six-month performance fell -31.33%. The stock lost -14.89% in the past year, while it has gained 45.45% so far this year. A look at the trailing 12-month EPS for PLX yields 0.04 with Next year EPS estimates of 0.45. For the next quarter, that number is 0.04. This implies an EPS growth rate of 250.00% for this year and 221.43% for next year.
Float and Shares Shorts:
At present, 78.13 million PLX shares are outstanding with a float of 73.81 million shares on hand for trading. On 2025-06-30, short shares totaled 3.27 million, which was 411.00003000000004 higher than short shares on 1748563200. In addition to Mr. Dror Bashan as the firm’s President, CEO & Director, Mr. Eyal Rubin M.B.A. serves as its Senior VP, CFO, Treasurer & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.10216 of PLX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, PLX reported revenue of $10113000.0 and operating income of -$4145000.0. The EBITDA in the recently reported quarter was -$3380000.0 and diluted EPS was -$0.05.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With PLX analysts setting a high price target of 15.0 and a low target of 13.0, the average target price over the next 12 months is 14.0. Based on these targets, PLX could surge 837.5% to reach the target high and rise by 712.5% to reach the target low. Reaching the average price target will result in a growth of 775.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.01667477 being high and $0.0075 being low. For PLX, this leads to a yearly average estimate of $0.015.
